Asparaginase
- Atc Codes:L01XX02
- CAS Codes:9015-68-3
- PHARMGKB ID:9015-68-3
Table of contents
- Brand Names
- Drug Combinations
- Chemistry
- Pharmacologic Category
- Mechanism of Action
- Therapeutic Use
- Unlabeled Use
- Pregnancy and Lactation Implications
- Contraindications
- Warnings and Precautions
- Adverse Reactions
- Genes that may be involved
- Drug Interactions
- Nutrition/Nutraceutical Interactions
- Dosage
- Pharmacokinetics and Pharmacodynamics
- Special Considerations
Brand Names
Europe
Belgium: Paronal; Czech Republic: Kidrolase; Estonia: Asparaginase; France: Kidrolase; Germany: Asparaginase; Greece: Asparaginase; Lithuania: Asparaginase; Malta: Asparaginase; Netherlands: Paronal; Poland: Asparaginase, Kidrolase; Romania: Asparaginase; Slovakia: Asparaginase.
North America
Canada: Kidrolase; USA: Elspar.
Latin America
Argentina: Kidrolase, Asparaginasa; Brazil: Elspar; Mexico: Elspar, Leunase.
Asia
Japan: Leunase.
Drug combinations
Asparaginase and Tryptophan
Chemistry
Asparaginase: Enzyme isolated from Escherichia coli, or obtained from other sources. L-Asparagine amidohydrolase. CAS-9015-68-3 (1970).
Pharmacologic Category
Other Antineoplastic Agents. Enzymes. (ATC-Code: L01XX02).
Mechanism of action
Inhibits protein synthesis by hydrolyzing asparagine to aspartic acid and ammonia.
Therapeutic use
Treatment of acute lymphocytic leukemia.
Pregnancy and lactiation implications
Use during pregnancy only if clearly needed. Not recommended during lactation.
Unlabeled use
Treatment of lymphoma.
Contraindications
Serious allergic reaction to asparaginase or any E. coli-derived asparaginase. Serious thrombosis with prior asparaginase treatment. Pancreatitis with prior asparaginase treatment. Serious hemorrhagic events with prior asparaginase treatment.
Warnings and precautions
Hazardous agent. Severe allergic reactions may occur. Use with caution in underlying coagulopathy (increased prothrombin time, partial thromboplastin time, hypofibrinogenemia, and cerebrovascular hemorrhage may occur). May cause hyperglycemia/glucose intolerance. Risk of pancreatitis. Thrombosis events (including sagittal sinus thrombosis) may occur. Possible tumor lysis syndrome and subsequent hyperuricemia and uric acid nephropathy. Use with caution in pre-existing hepatic impairment.